成人肺炎性肌纤维母细胞瘤1例

患者,女,52岁,因"胸闷气喘伴干咳1周"于2009年8月14日入我院.否认家族性肿瘤病史.胸片:右下肺巨大占位.胸部B超:右下肺内大小约8cmx8cm的稍低回声区,边界清晰,内部回声分布不均匀,可见散在强回声光点,光斑、后伴淡声影,CDFI示内部可见长条状血流信号.胸部CT:右肺下叶恶性占位并侵犯右下肺动脉及右上、下肺静脉.     

伴有淋巴结转移的肺炎性肌纤维母细胞瘤1例

1例病理诊断为肺炎症性肌纤维母细胞瘤的患者,肺部病变伴有全身多处淋巴结肿大,全身化疗后效果明显。提示炎性肌纤维母细胞瘤虽然是一种低度恶性肿瘤,但可发生全身转移,化疗有效。     

伴有淋巴结转移的肺炎性肌纤维母细胞瘤1例

1例病理诊断为肺炎症性肌纤维母细胞瘤的患者,肺部病变伴有全身多处淋巴结肿大,全身化疔后效果明显.提示炎性肌纤维母细胞瘤虽然是一种低度恶性肿瘤,但可发生全身转移,化疗有效.     

大腿炎性肌纤维母细胞瘤伴肺、肝转移１例

1病案摘要 患者男性,51岁,汉族。10余年前发现左大腿外侧皮下一花生米大小肿物,无疼痛不适,未诊治。2002年5月因肿物增大如鹅蛋大小,在外院手术切除,术后未行病理检查。2004年6月在左大腿外侧手术疤痕处肿物复发,缓慢生长,至2007年12月增大至成人拳头大小,到当地县医院手术切除,术后病理不详。2008年1月再次发现手术疤痕处出现肿物,生长快,2008年5月肿物增大如鹅蛋大小,遂到省级医院行手术切除,术后病理示：炎性肌纤维母细胞瘤（低度恶性）。     

肺巨大炎性肌纤维母细胞瘤伴发脑转移1例临床病理分析

0引言 炎性肌纤维母细胞瘤(inflammatory myofibroblastic tumor,IMT)以往认为是非肿瘤性增生,命名相当混乱,如炎性假瘤、浆细胞肉芽肿、纤维黄色瘤等.新的WHO软组织肿瘤分类[1]将其归为纤维母细胞/肌纤维母细胞肿瘤、中间性、少数可转移.目前对于该病的病理特点已经有了全新的认知,临床医生在治疗观念上也得到了更新.本文拟通过肺炎性肌纤维母细胞瘤伴发脑转移临床病理分析及文献复习.探讨其组织学诊断特点和外科治疗方法.     

多发性炎性肌纤维母细胞瘤1例

<正>患者,女,66岁。因发现颈部肿物两年,咽部肿物伴声音嘶哑半年于2006年3月入院。     

14例肺炎性肌纤维母细胞瘤的临床病理研究

背景与目的 炎性肌纤维母细胞瘤（Inflammatory myofihroblastic tumor，IMT）是一种较为少见的好发于肺脏的真性肿瘤。本文旨在探讨肺IMT的外科临床病理特点及治疗和预后。方法 自1999年1月至2003年12月，同济医院胸心外科共收治14例肺IMT患者。切除标本均经病理组织学、免疫组织化学检查确立诊断。所有患者均接受1～5年的随访。结果 14例患者中男性8例，女性6例，年龄11～46岁。9例患者无临床症状。5例表现为咳嗽、咳血及气短等症状。IMT的诊断均通过外科切除后病理检查确立。切除肿瘤大小从1～8cm不等。病理组织学上IMT主要由梭形细胞和各种炎性细胞组成，梭形细胞在超微结构上表现为肌纤维母细胞和纤维母细胞。本组所有患者手术切除后无临床复发，随访预后良好。结论 病理组织学上。IMT是以肌纤维母细胞混以各类炎性细胞为特征，其中包括浆细胞、淋巴细胞和组织细胞。外科手术完整切除肿瘤是治疗IMT的首选方法并且预后良好。     

纵隔炎性肌纤维母细胞瘤化疗完全缓解1例

患者,男性,45岁,胸骨前包块及左锁骨上淋巴结肿大2个月,无发热,盗汗.2008年10月8日行胸部CT检查示(图1):前纵隔内不规则软组织密度影;B超示:左锁骨上淋巴结肿大;PET-CT示:前纵隔FDG代谢异常增高,左锁骨E肿大淋巴结FDG代谢异常增高.2008年11月7日行左锁骨上肿大淋巴结切除,术后病理:左锁骨上炎性肌纤维母细胞瘤.免疫组化:Vim(++),SMA(+++).确诊后给予CAP(环磷酰     

胃巨大炎性肌纤维母细胞瘤1例报道

正炎性肌纤维母细胞瘤(inflammatory myofibroblastic tumor,IMT)是由分化的肌纤维母细胞性梭形细胞组成,常伴浆细胞和(或)淋巴细胞浸润的一种间叶性肿瘤。IMT最常见于肺部,腹腔内罕见,而腹腔内IMT多见于肝脾,胃肠道的发生率更低,关于胃肠道IMT发病率的统计尚未有报道。2013年3月我院收治1例胃巨大炎性肌纤维母细胞瘤,现报道分析如下。1临床资料患者女性,66岁,因上腹部饱胀不适2月于2013-03-12入院,伴贫血,恶心,无呕吐,发热,纳眠     

Inflammatory Myofibroblastic Tumor of the Urinary Bladder with Benign Pelvic Lymph Node Enlargement: A Case Report

Inflammatory myofibroblastic tumors (IMTs) rarely occur in the urinary bladder. It is apparently difficult to distinguish these tumors from other malignant spindle cell proliferations. Herein, we report a case of IMT of the urinary bladder with enlarged pelvic lymph nodes. The definitive pathological diagnosis could not be established by biopsy. Instead, the diagnosis of IMT of the urinary bladder was determined by a positive reaction to anaplastic lymphoma kinase by immunohistochemistry after radical cystectomy. No malignant findings were observed on histopathological evaluations of the enlarged lymph nodes.Key words: Inflammatory myofibroblastic tumor, Urinary bladder, Lymph node swelling     

Inflammatory Myofibroblastic Tumor of Mesentery: A Case Report

Introduction

Inflammatory myofibroblastic tumor occurring at intra-abdominal sites in children has rarely been described. In the abdomen, mesentery is a rare location for an inflammatory myofibroblastic tumor.

Case report

A case report of inflammatory myofibroblastic tumor of mesentery presenting as painless abdominal swelling is presented. Histopathological study of specimen documented the diagnosis. Complete resection of tumor was done with no recurrence seen in follow-up.     

Transrectal Ultrasonography of a Small Rectal Carcinoid Tumor with Lymph Node Metastasis: A Case Report

A 27-year-old woman with a small rectal carcinoid tumor wasexamined by transrectal ultrasonography (TRUS) for preoperativestaging. TRUS revealed regional lymph node involvement, in additionto a 10-mm hypoechoic tumor invading into, but not through,the submucosa. The lymph node involvement was confirmed preoperativelyby TRUS-guided needle biopsy. Although the digital examinationfindings indicated local excision was appropriate, in accordancewith TRUS and TRUS-guided biopsy findings, the patient underwentradical surgery. The TRUS findings of lymph node involvementand depth of invasion were confirmed histologically. The patientis alive and disease-free 35 months postoperatively. These observationssuggest that TRUS reveals the regional lymph node involvementand the depth of invasion of rectal carcinoid tumors accuratelyand, therefore, helps in selecting appropriate treatment.     

Case Report: Inflammatory Myofibroblastic Tumor of the Duodenum

Introduction

We report a very rare case of inflammatory myofibroblastic tumor of the duodenum. A 16-year-old boy underwent esophagogastroduodenoscopy for intermittent epigastric pain, night sweats, and malaise.

Case Report

An exophytic mass lesion was found in the first part of the duodenum, but biopsies were non-diagnostic. Computed tomography confirmed a 60-mm mass with no lymphadenopathy, and the patient underwent surgical resection. Histology revealed spindle cells with the morphological and immunophenotypical profile of myofibroblasts on a background of mixed inflammatory infiltrate, typical of inflammatory myofibroblastic tumor. Six months after surgery, the patient developed a recurrence, and this was successfully treated by immunosupression. Currently, the patient is asymptomatic, and there is no radiological or pathological evidence of disease.     

肺腺癌心脏转移1例报道

肺癌是心脏恶性转移瘤中最常见的原发肿瘤，临床上心脏作为肿瘤的靶器官容易被忽略。我科最近收治1例肺腺癌心脏转移患者，报道如下。 1临床资料     

肺炎症性肌纤维母细胞瘤12例临床病理分析

[目的]探讨肺炎症性肌纤维母细胞瘤的病理认识演变和临床特点.[方法]回顾性分析中国医学科学院肿瘤医院胸外科自2005年到2009年间收治的12例肺炎症性肌纤维母细胞瘤病例的临床资料和诊治特点.[结果]本组共12例,占同期肺外科手术的0.23％(12/5 176).其中男性9例,女性3例;平均年龄53.8岁;病灶呈周围型...     

肺癌患者淋巴结转移规律及其相关因素分析

摘 要：［目的］ 探讨肺癌患者发生淋巴结转移的规律及影响淋巴结转移的因素。［方法］ 对既往行肺癌根治性切除术治疗的209例患者进行回顾性分析,对发生淋巴结转移的分布规律及其影响因素进行统计分析。［结果］ 209例患者,共清扫淋巴结974枚,其中发生淋巴结转移223枚（22.90%）,发生淋巴结转移的患者有81例（38.76%）。淋巴结转移率较高的组分别为第11组（30.43%）、第4组（28.00%）、第3组（27.45%）,淋巴结转移率较低的组分别为第9组（10.59%）、第1组（14.71%）、第8组（16.00%）。肿瘤的病理类型为腺癌（OR=1.892）、中央型肺癌（OR=1.528）、低分化程度（OR=1.633）是肺癌患者发生淋巴结转移的危险因素（P<0.05）,与患者是否吸烟关系不密切（P>0.05）。［结论］ 淋巴结转移主要与病理类型、病灶部位、分化程度有关,淋巴结转移规律分析有利于为手术患者术中扫除淋巴结和放疗患者靶区规划提供参考依据。     

A Common Cell of Origin for Inflammatory Myofibroblastic Tumor and Lung Adenocarcinoma with ALK rearrangement

This case signifies the importance of obtaining tumor comprehensive genomic profiling (CGP) as it has utility in cancer type classification and helping in diagnosing recurrence/metastasis or separately occurring primary tumors. CGP can also help guiding treatment as in this case separately occurring Inflammatory Myofibroblastic Tumor had ALK fusion and responded to crizotinib. As treatment progresses, new biopsies should be obtained and CGP used to evaluate for appearance of any new genomic alterations, in order to guide further therapy.